ANTIGENIC AND ENZYME SYSTEM CHANGES IN BETA HEMOLYTIC STREPTOCOCCI RESISTANT TO PENICILLIN, STREPTOMYCIN, BACITRACIN AND AUREOMYCIN

Horace M. Gezon; Dorcas M. Fasan

doi:10.1172/JCI102172

^{Department of Pediatrics, University of Chicago}

Presented at the Second National Symposium on Recent Advances in Antibiotics Research held in Washington, D. C., April 11-12, 1949, under the auspices of the Antibiotics Study Section, National Institutes of Health, Public Health Service, Federal Security Agency.

This investigation was supported (in part) by a research grant from the Division of Research Grants and Fellowships of the National Institutes of Health, U. S. Public Health Service, and by a research grant from The Abbott Laboratories.

Aureomycin was supplied by the Lederle Laboratories Division, American Cyanamid Co., through the Antibiotics Study Section of the National Institutes of Health.

Bacitracin was supplied by the Commercial Solvents Corporation, through the Antibiotics Study Section of the National Institutes of Health, and by Dr. Frank L. Meleney of Columbia University.

Find articles by Gezon, H. in: JCI | PubMed | Google Scholar

^{Department of Pediatrics, University of Chicago}

Aureomycin was supplied by the Lederle Laboratories Division, American Cyanamid Co., through the Antibiotics Study Section of the National Institutes of Health.

Bacitracin was supplied by the Commercial Solvents Corporation, through the Antibiotics Study Section of the National Institutes of Health, and by Dr. Frank L. Meleney of Columbia University.

Find articles by Fasan, D. in: JCI | PubMed | Google Scholar